Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Beijing Tiantan Biological Products Co., Ltd.
  6. News
  7. Summary
    600161   CNE000000WF9

BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.

(600161)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2020

08/27/2020 | 05:41am EST

Beijing Tiantan Biological Products Co., Ltd. announced earnings results for the half year ended June 30, 2020. For the half year, the company announced sales was CNY 1,554.808 million compared to CNY 1,560.338 million a year ago. Operating income was CNY 495.439 million compared to CNY 514.849 million a year ago. Net income was CNY 283.689 million compared to CNY 293.646 million a year ago. Basic earnings per share from continuing operations was CNY 0.27 compared to CNY 0.28 a year ago.


ę S&P Capital IQ 2020
All news about BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.
12/03Peijia Medical Chairman, Senior Management Propose Purchase of Shares in Firm
MT
10/27Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the Nine Mon..
CI
07/14Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the Half Yea..
CI
04/29BEIJING TIANTAN BIOLOGICAL PRODUCTS : Indonesia approves Sinopharm COVID-19 vaccine for em..
RE
04/26Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the First Qu..
CI
04/16EXCLUSIVE : Sinopharm to inject $4.6 billion vaccine assets into unit Tiantan Biological -..
RE
04/16Sinopharm plans to inject $4.6 bln in assets into unit beijing tiantan biological produ..
RE
2020BEIJING TIANTAN BIOLOGICAL PRODUCTS : 600161) added to Shanghai Stock Exchange 180 Value ..
CI
2020BEIJING TIANTAN BIOLOGICAL PRODUCTS : 600161) added to SSE 180 Index
CI
2020Beijing Tiantan Biological Products Co., Ltd. Reports Earnings Results for the Nine Mon..
CI
More news
Financials
Sales 2021 3 944 M 622 M 622 M
Net income 2021 760 M 120 M 120 M
Net Debt 2021 - - -
P/E ratio 2021 52,4x
Yield 2021 0,40%
Capitalization 39 712 M 6 260 M 6 260 M
Capi. / Sales 2021 10,1x
Capi. / Sales 2022 8,66x
Nbr of Employees 3 592
Free-Float 41,1%
Chart BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.
Duration : Period :
Beijing Tiantan Biological Products Co., Ltd. Technical Analysis Chart | 600161 | CNE000000WF9 | MarketScreener
Technical analysis trends BEIJING TIANTAN BIOLOGICAL PRODUCTS CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 28,92 CNY
Average target price 38,40 CNY
Spread / Average Target 32,8%
EPS Revisions
Managers and Directors
Dao Xing Fu General Manager & Director
Yi Zhang Chief Financial Officer & Deputy General Manager
Xiao Ming Yang Chairman
Jing Jin Zhu Chairman-Supervisory Board
Hong Guang Wang Independent Director
Sector and Competitors